- Home
- SXTP vs SLRX Comparison
SXTP vs SLRX Comparison
Compare SXTP & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTP | SLRX |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SXTP | SLRX |
|---|---|---|
| Price | $0.80 | $0.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.40 | N/A |
| AVG Volume (30 Days) | 82.6K | ★ 664.7K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,364,945.00 | N/A |
| Revenue This Year | $146.28 | N/A |
| Revenue Next Year | $24.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 202.10 | N/A |
| 52 Week Low | $0.84 | $0.71 |
| 52 Week High | $11.35 | $108.00 |
Technical Indicators
Market Signals| Indicator | SXTP | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 23.94 | 27.29 |
| Support Level | $0.84 | $0.81 |
| Resistance Level | $0.98 | $0.89 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 3.64 | 15.00 |
Price Performance
Historical ComparisonAbout SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.